{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:11:06Z","timestamp":1738645866935,"version":"3.35.0"},"reference-count":82,"publisher":"Edizioni Minerva Medica","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ital J Dermatol Venereol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.23736\/s2784-8671.24.08083-6","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:16:21Z","timestamp":1738581381000},"source":"Crossref","is-referenced-by-count":0,"title":["Biosimilars for the treatment of psoriasis: a narrative review"],"prefix":"10.23736","volume":"159","author":[{"given":"Duc B.","family":"PHAN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenas Z.","family":"YIU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17149","reference":[{"key":"10.23736\/S2784-8671.24.08083-6_ref001","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"4","author":"Sbidian E","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.23736\/S2784-8671.24.08083-6_ref002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"10.23736\/S2784-8671.24.08083-6_ref003","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5264"},{"key":"10.23736\/S2784-8671.24.08083-6_ref004","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0029-z"},{"key":"10.23736\/S2784-8671.24.08083-6_ref005","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-015-0169-x"},{"key":"10.23736\/S2784-8671.24.08083-6_ref006","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213289"},{"key":"10.23736\/S2784-8671.24.08083-6_ref007","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202603"},{"key":"10.23736\/S2784-8671.24.08083-6_ref008","unstructured":"EMA. Biosimilar medicines: marketing authorisation 2014 [Internet]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/marketing-authorisation\/biosimilar-medicines-marketing-authorisation [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref009","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00507-1"},{"key":"10.23736\/S2784-8671.24.08083-6_ref010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040528"},{"key":"10.23736\/S2784-8671.24.08083-6_ref011","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0117"},{"key":"10.23736\/S2784-8671.24.08083-6_ref012","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-020-00245-0"},{"key":"10.23736\/S2784-8671.24.08083-6_ref013","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-016-0041-3"},{"key":"10.23736\/S2784-8671.24.08083-6_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2019.06.008"},{"key":"10.23736\/S2784-8671.24.08083-6_ref015","unstructured":"GaBI Online. Biosimilars approved in Europe 2024 [Internet]. Available from: https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref016","unstructured":"WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009. [Internet]. Available from: http:\/\/www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf c"},{"key":"10.23736\/S2784-8671.24.08083-6_ref017","unstructured":"EMA. Guideline on similar biological medicinal products 2014 [Internet]. Available from: www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref018","unstructured":"FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product 2015 [Internet]. Available from:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref019","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15756"},{"key":"10.23736\/S2784-8671.24.08083-6_ref020","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12294"},{"key":"10.23736\/S2784-8671.24.08083-6_ref021","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0230-9"},{"key":"10.23736\/S2784-8671.24.08083-6_ref022","unstructured":"National Psoriasis Foundation. Biosimilar substitution 2015 [Internet]. Available from: https:\/\/www.psoriasis.org\/about-psoriasis\/treatments\/statement-on-biosimilars [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref023","unstructured":"American Academy of Dermatology. Position statement on generic therapeutic & biosimilar substitution 2013 [Internet]. Available from: https:\/\/www.aad.org\/Forms\/Policies\/Uploads\/PS\/PS-Generic%20Therapeutic%20and%20%20Biosimilar%20Substitution.pdf [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref024","unstructured":"Canadian Association of Psoriasis Patients. Our position on biosimilars: additional considerations 2014 [Internet]. Available from: http:\/\/www.canadianpsoriasis.ca\/index.php\/en\/biosimilars\/our-position [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref025","doi-asserted-by":"publisher","DOI":"10.20344\/amp.8118"},{"key":"10.23736\/S2784-8671.24.08083-6_ref026","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2015.03.001"},{"key":"10.23736\/S2784-8671.24.08083-6_ref027","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2016.04.001"},{"key":"10.23736\/S2784-8671.24.08083-6_ref028","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.120531"},{"key":"10.23736\/S2784-8671.24.08083-6_ref029","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2016.1272308"},{"key":"10.23736\/S2784-8671.24.08083-6_ref030","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00288"},{"key":"10.23736\/S2784-8671.24.08083-6_ref031","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2016-000904"},{"key":"10.23736\/S2784-8671.24.08083-6_ref032","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01951-z"},{"key":"10.23736\/S2784-8671.24.08083-6_ref033","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.11.009"},{"key":"10.23736\/S2784-8671.24.08083-6_ref034","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0252-3"},{"key":"10.23736\/S2784-8671.24.08083-6_ref035","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204020"},{"key":"10.23736\/S2784-8671.24.08083-6_ref036","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.1338"},{"key":"10.23736\/S2784-8671.24.08083-6_ref037","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2235263"},{"key":"10.23736\/S2784-8671.24.08083-6_ref038","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.04.045"},{"key":"10.23736\/S2784-8671.24.08083-6_ref039","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00630-5"},{"key":"10.23736\/S2784-8671.24.08083-6_ref040","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000154"},{"key":"10.23736\/S2784-8671.24.08083-6_ref041","unstructured":"NCT03849404. Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis 2019 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03849404 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref042","unstructured":"NCT01970488. Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA) in Adults With Moderate to Severe Plaque Psoriasis 2014 [Internet]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01970488 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref043","unstructured":"NCT02762955. Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira in Patients With Moderate to Severe Plaque Psoriasis 2017 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02762955 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref044","unstructured":"NCT02850965. Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis 2018 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02850965 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref045","unstructured":"NCT04673786. A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis 2021 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04673786 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref046","unstructured":"NCT02489227. Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis 2016 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02489227 [cited 2022, Aug 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref047","unstructured":"NCT02134210. Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) 2015 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02134210 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref048","unstructured":"NCT02660580. MSB11022 in Moderate to Severe Chronic Plaque Psoriasis 2016 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02660580"},{"key":"10.23736\/S2784-8671.24.08083-6_ref049","unstructured":"NCT02581345. Phase 3 Study of M923 and Humira in Subjects With Chronic Plaque-type Psoriasis 2017 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02581345 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref050","unstructured":"NCT01891864. Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel 2014 [Internet]. Available from:https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01891864 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref051","unstructured":"NCT02016105. Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira 2015 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02016105 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref052","unstructured":"NCT03316781. Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis 2018 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03316781 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref053","unstructured":"NCT03210259. The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira and BI 695501 in Patients With Plaque Psoriasis 2019 [Internet]. Available from: Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03210259 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref054","unstructured":"NCT02148640. The NOR-SWITCH Study 2016 [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02148640 [cited 2024, Jul 10]."},{"key":"10.23736\/S2784-8671.24.08083-6_ref055","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"10.23736\/S2784-8671.24.08083-6_ref056","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17849"},{"key":"10.23736\/S2784-8671.24.08083-6_ref057","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1923467"},{"key":"10.23736\/S2784-8671.24.08083-6_ref058","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13435"},{"key":"10.23736\/S2784-8671.24.08083-6_ref059","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14258"},{"key":"10.23736\/S2784-8671.24.08083-6_ref060","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18090"},{"key":"10.23736\/S2784-8671.24.08083-6_ref061","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0769-7"},{"key":"10.23736\/S2784-8671.24.08083-6_ref062","first-page":"316","article-title":"Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)","volume":"19","author":"Egeberg A","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"10.23736\/S2784-8671.24.08083-6_ref063","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12846"},{"key":"10.23736\/S2784-8671.24.08083-6_ref064","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17133"},{"key":"10.23736\/S2784-8671.24.08083-6_ref065","first-page":"1","article-title":"Efficacy and safety of infliximab biosimilar in the treatment of moderate-to-severe plaque psoriasis: A 52-week clinical study","volume":"81","author":"Panagakis P","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.23736\/S2784-8671.24.08083-6_ref066","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.068"},{"key":"10.23736\/S2784-8671.24.08083-6_ref067","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20198358"},{"key":"10.23736\/S2784-8671.24.08083-6_ref068","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19013"},{"key":"10.23736\/S2784-8671.24.08083-6_ref069","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15755"},{"key":"10.23736\/S2784-8671.24.08083-6_ref070","doi-asserted-by":"publisher","DOI":"10.23736\/S2784-8671.22.07224-3"},{"key":"10.23736\/S2784-8671.24.08083-6_ref071","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"key":"10.23736\/S2784-8671.24.08083-6_ref072","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.0221"},{"key":"10.23736\/S2784-8671.24.08083-6_ref073","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034183"},{"key":"10.23736\/S2784-8671.24.08083-6_ref074","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2835-4"},{"key":"10.23736\/S2784-8671.24.08083-6_ref075","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2015.1054422"},{"key":"10.23736\/S2784-8671.24.08083-6_ref076","first-page":"336","article-title":"The Current State of Dermatologists' Familiarity and Perspectives of Biosimilars for the Treatment of Psoriasis: A Global Cross-Sectional Survey","volume":"16","author":"Manalo IF","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"10.23736\/S2784-8671.24.08083-6_ref077","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0431-5"},{"key":"10.23736\/S2784-8671.24.08083-6_ref078","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-050949"},{"key":"10.23736\/S2784-8671.24.08083-6_ref079","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15856"},{"key":"10.23736\/S2784-8671.24.08083-6_ref080","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2018.1427065"},{"key":"10.23736\/S2784-8671.24.08083-6_ref081","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14178"},{"key":"10.23736\/S2784-8671.24.08083-6_ref082","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.208"}],"container-title":["Italian Journal of Dermatology and Venereology"],"original-title":[],"link":[{"URL":"https:\/\/www.minervamedica.it\/pdf.php?cod=R23Y2024N06A0663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:16:59Z","timestamp":1738581419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.minervamedica.it\/index2.php?show=R23Y2024N06A0663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":82,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.23736\/s2784-8671.24.08083-6","relation":{},"ISSN":["2784-8671","2784-8450"],"issn-type":[{"value":"2784-8671","type":"print"},{"value":"2784-8450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}